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Introduction
The treatment of hepatocellular carcinoma (HCC) follows well established guidelines. [1] [2] [3] Surgical resection, trans plantation, and ablation are potential curative options for early-stage disease, whereas chemoembolisation is recommended for patients with preserved liver function and disease confi ned to the liver generally without vascular invasion. For patients who are not or who are no longer candidates for locoregional therapy, the oral multikinase inhibitor sorafenib is the only systemic treatment shown to provide a clinically signifi cant improvement in overall survival. 4, 5 Since the results with sorafenib were published almost 10 years ago, all phase 3 trials assessing novel systemic drugs have failed to improve outcomes over sorafenib in the fi rst-line setting [6] [7] [8] [9] [10] or in the second-line setting following sorafenib. [11] [12] [13] [14] In second-line trials in patients who have failed sorafenib, overall survival in the placebo group is about 8 months. [11] [12] [13] [14] Therefore, there is an unmet need for eff ective systemic therapies for HCC, particularly after treatment with sorafenib.
Regorafenib is an oral multikinase inhibitor that blocks the activity of protein kinases involved in angiogenesis, oncogenesis, metastasis, and tumour immunity. 15, 16 It has a distinct molecular target profi le and had more potent pharmacological activity than sorafenib in preclinical studies. 15, 17 Regorafenib is approved as monotherapy for the treatment of treatment-refractory metastatic colorectal cancer and gastrointestinal stromal tumours at a dose of 160 mg once daily for the fi rst 3 weeks of each 4-week cycle. [18] [19] [20] Based on results of a single-arm phase 2 study showing antitumour activity and acceptable tolerability, 21 we aimed to assess the effi cacy and safety of regorafenib in patients with HCC who progressed during sorafenib treatment.
Methods

Study design and participants
This randomised, double-blind, placebo-controlled international phase 3 trial was done at 152 centres in 21 countries in North America, South America, Europe, Asia, and Australia.
Eligible patients were adults with HCC confi rmed by pathological assessment or non-invasive assessment according to the American Association for the Study of Liver Diseases criteria for patients with confi rmed cirrhosis, 1 and had to have at least one measurable lesion by modifi ed Response Evaluation Criteria in Solid Tumors for HCC (mRECIST) 22 and RECIST version 1.1. Patients were Barcelona Clinic Liver Cancer (BCLC) stage B or C, 23 could not benefi t from resection, local ablation, or chemoembolisation, and must have had documented radiological progression during sorafenib treatment as defi ned in a study-specifi c radiology charter. They must have tolerated sorafenib (≥400 mg daily for at least 20 of the 28 days before discontinuation) and received their last sorafenib dose within 10 weeks of randomisation. They were required to have Child-Pugh A liver function. Patients were excluded if they had received any other previous systemic treatment for HCC or if they discontinued sorafenib for toxicity (see appendix pp 5-7 for full inclusion and exclusion criteria).
All patients provided written informed consent. The trial was approved by each centre's ethics committee or institutional review board and complied with Good Clinical Practice guidelines, the Declaration of Helsinki, and applicable local laws.
Randomisation and masking
Patients were randomly assigned (2:1) to regorafenib or placebo using a computer-generated randomisation list prepared by the funder. Randomisation was stratifi ed by geographical region (Asia vs rest of world), macrovascular invasion (yes vs no), extrahepatic disease (yes vs no), α-fetoprotein concentration (<400 ng/mL vs ≥400 ng/mL), and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs 1). The proportion of patients recruited from Asia was limited to 40%. Investigators, patients, and the funder were masked to treatment
Research in context
Evidence before this study We searched PubMed for articles published between Jan 1, 2008, and Oct 26, 2016, with no language restrictions, reporting on the treatment of patients with advanced hepatocellular carcinoma (HCC) who failed sorafenib treatment using the search terms ("advanced hepatocellular carcinoma" OR "advanced hepatocellular cancer") AND "sorafenib", fi ltering for articles describing phase 3 clinical trials. We also searched abstracts of the annual meeting of the American Society of Clinical Oncology, using the search term "advanced hepatocellular carcinoma'', limiting the results to phase 3 trials published or presented during the past 2 years. The search resulted in 15 articles or abstracts, of which three were excluded (two subanalyses and one report of maintenance sorafenib therapy following the combination of transcatheter arterial chemoembolisation and radiotherapy). Of the remaining 12 publications, two were reports of the pivotal trials of sorafenib for advanced HCC; fi ve reported the fi rst-line use of a novel drug or the novel combination of a drug with sorafenib compared with a sorafenib control; and fi ve reported the second-line use of a novel agent in patients who had failed sorafenib. None of the trials assessing novel agents or novel combinations of agents in the fi rst-line setting met the primary endpoint to show improved overall survival over sorafenib.
Similarly, none of the drugs assessed in the second-line setting in patients previously treated with sorafenib who stopped because of disease progression or intolerance showed improvement over placebo. Therefore, new eff ective systemic therapies for patients with advanced HCC who fail sorafenib treatment are needed.
Added value of this study
Until now, no systemic agent has been shown to improve survival over placebo in patients with advanced HCC who fail sorafenib treatment. The results of RESORCE show that treatment with regorafenib resulted in a signifi cant improvement in overall survival compared with placebo in patients with disease progression on sorafenib. Signifi cant improvement over placebo was also shown for the secondary endpoints of progression-free survival, time to progression, disease control, and overall tumour response.
Implications of all the available evidence
This phase 3 trial of regorafenib is the fi rst to show an overall survival benefi t compared with placebo in patients who failed sorafenib treatment. Future trials should explore combinations of regorafenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafenib and regorafenib. assignment. The randomisation number for each patient was assigned based on information obtained from the interactive voice-response system. Tablets with identical appearance were used for regorafenib and placebo.
Procedures
Patients received 160 mg regorafenib (four 40 mg tablets) orally or matching placebo once daily for the fi rst 3 weeks of each 4-week cycle. All patients received best supportive care. Other investigational antitumour drugs, antineoplastic chemotherapy, hormonal therapy, or immunotherapy were not allowed. Treatment continued until disease progression as defi ned by mRECIST, clinical progression (defi ned as an ECOG performance score ≥3 or symptomatic deterioration, including increased liver function tests), death, unacceptable toxicity, withdrawal of consent by the patient, or decision by the treating physician that discontinuation would be in the patient's best interest. Patients were followed up for tumour assessments every 6 weeks for the fi rst eight cycles and every 12 weeks thereafter during treatment. Treatment could be continued beyond progression if the investigator judged that the patient would benefi t from continued treatment. Patients assigned to placebo could receive regorafenib after the primary analysis.
Treatment interruptions and dose reductions (to 120 mg, then 80 mg) were allowed to manage toxicity (appendix pp [12] [13] [14] [15] . The regorafenib dose could be reescalated to a maximum of 160 mg at the investigator's discretion once toxicities were resolved. If further dose reduction was required, treatment was discontinued.
Outcomes
The primary endpoint was overall survival (time from randomisation to death due to any cause), analysed by intention to treat (ITT). Secondary effi cacy endpoints were progression-free survival (randomisation to radiological or clinical disease progression or death; by ITT), time to progression (randomisation to radiological or clinical disease progression; by ITT), objective response rate (patients with complete or partial response), and disease control rate (patients with complete response, partial response, or stable disease maintained for ≥6 weeks), assessed by investigators using mRECIST 22 and RECIST 1.1 (appendix p 7).
Health-related quality of life (HRQoL) was a teritiary outcome assessed using the Functional Assessment of Cancer Therapy (FACT)-General (FACT-G), FACT-Hepatobiliary (FACT-Hep), EQ-5D, and EQ-VAS questionnaires. 24, 25 The following tertiary endpoints are not reported here: pharmacokinetics of regorafenib, and biomarker evaluation. Safety was assessed by adverse events, laboratory abnormalities, vital signs, and electrocardiography. Safety was monitored continuously throughout the study, and patients underwent safety evaluations at every cycle. Concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin were assessed weekly during the fi rst two cycles. Adverse events were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 (appendix p 7 for further assessments) and seriousness of adverse events was recorded. Investigators were blinded to study treatment for assessment of whether a death was considered related to study drug.
Statistical analysis
Using a per-protocol one-sided α of 0·025, a 2:1 randomisation between regorafenib and placebo, and assuming a median overall survival of 8 months in the placebo group, the study would have 90% power to detect a 43% increase in overall survival with regorafenib (assumed median survival 11·4 months) compared with placebo at 370 deaths and requiring 560 patients. For the primary effi cacy endpoint of overall survival, the groups were compared using a log-rank test, stratifi ed by the aforementioned randomisation factors. The hazard ratio (HR) for overall survival and its 95% CI were calculated using the stratifi ed Cox model. An interim futility analysis was done after 30% of the events had occurred; futility boundaries were not crossed. For analyses of time to progression and progression-free survival, groups were compared using a log-rank test stratifi ed by the factors used in the analyses of the primary endpoint. The response rates and disease control rates in the two groups were compared using the Cochran-Mantel-Haenszel test, with adjustment for the stratifi cation factors.
For HRQoL assessments, an analysis-of-covariance model was used to compare the time-adjusted area under the curve (AUC) between groups with covariates for baseline scores and stratifi cation factors. The least-squares mean (LSM) with 95% CI was estimated for each treatment group and for the diff erence between groups.
Data were analysed with SAS, version 9.2 (SAS Institute Inc, Cary, NC, USA). The primary analysis was by intention to treat; safety analyses included all patients who received at least one dose of study drug. The study was overseen by a data safety monitoring committee.
This trial is registered with ClinicalTrials.gov, number NCT01774344. 
Regorafenib
Role of the funding source
The funder (Bayer) provided the study drug and worked with the principal investigator (JB) and the study steering committee to design the study. Data collection and interpretation, and preparation of this report, were done by the investigators and the funder. Statistical analyses were performed by the funder. All authors reviewed this report and approved the submission for publication, had full access to the data, and vouch for the completeness and accuracy of the data and adherence of the study to the protocol. The funder funded writing assistance.
Results
Between May 14, 2013, and Dec 31, 2015, 843 patients were screened, of whom 573 were enrolled and randomised (379 to regorafenib and 194 to placebo; population for effi cacy analyses; fi gure 1). 216 patients (38%) were from Asia. Overall, 567 patients (99%) started treatment (374 in the regorafenib group and 193 in the placebo group) and comprise the safety analysis population. Treatment groups were similar with respect to baseline demographics, tumour burden, ECOG performance status, aetiology, and severity of liver disease (table 1) . We also assessed the pattern of progression during sorafenib treatment because this parameter has been shown to infl uence outcomes and could distort the results of second-line studies. 26 A potential imbalance in the pattern of progression on previous sorafenib was ruled out because the distribution of the diff erent categories was similar across the treatment groups. Specifi cally, the development of new extrahepatic sites during previous sorafenib, which was recently shown to be associated with a worse prognosis, 26 Of patients who started treatment, 309 (83%) receiving regorafenib and 183 (95%) receiving placebo discontinued study treatment (fi gure 1). The most common reason for discontinuation was disease progression (226 [60%] in the regorafenib group and 162 [84%] in the placebo group). Median treatment duration was 3·6 months (IQR 1·6-7·6) with regorafenib and 1·9 months (1·4-3·9) with placebo; mean durations were 5·9 months (SD 6·0) and 3·3 months (3·9), respectively. Mean daily dose of regorafenib was 144·1 mg (SD 21·3) and of placebo was 157·4 mg (10·3). Excluding treatment delays or interruptions, almost half of the regorafenib group (184 [49%] of 374]) received the full protocol dose (160 mg/day) with no reductions.
At the cutoff date for the fi nal analysis (Feb 29, 2016) and a median follow-up of 7·0 months (IQR 3·7-12·6), 0  3  6  9  12  15  18  21  24  27  30  33   0  3  6  9  12  15  18  21  24  27  30  33   0  3  6  9  12  15  18  21  24  27  30  33   379  164  75  41  27  14  8 Median progression-free survival by mRECIST was 3·1 months (95% CI 2·8-4·2) with regorafenib and 1·5 months (1·4-1·6) with placebo (fi gure 2B). Median time to progression by mRECIST was 3·2 months (95% CI 2·9-4·2) with regorafenib and 1·5 months (1·4-1·6) with placebo (fi gure 2C). Predefi ned subgroup analysis for progression-free survival and time to progression also showed a consistent benefi t (fi gures 3B,C). The HRs for progression-free survival and time to progression assessed by RECIST 1.1 were comparable (appendix pp [8] [9] [10] [11] .
Favours placebo Favours regorafenib
Two patients (1% [95% CI <1-2]) in the regorafenib group versus no patients in the placebo group had a complete response and 38 patients (10% [7] [8] [9] [10] [11] [12] [13] [14] ) in the regorafenib group versus eight patients (4% [2] [3] [4] [5] [6] [7] [8] ) in the placebo group had a partial response by mRECIST as assessed by investigators ( . Serious adverse events occurred in 166 (44%) patients assigned to regorafenib and 90 (47%) patients assigned to placebo and were attributed to study drug in 39 (10%) patients assigned to regorafenib and fi ve (3%) patients assigned to placebo. Of the 88 deaths (grade 5 adverse events) reported during the study (50 patients [13%] assigned to regorafenib and 38 [20%] assigned to placebo), seven (2%) were considered by the investigator to be related to study drug in the regorafenib arm and two (1%) in the placebo arm, including two patients (1%) with hepatic failure in the placebo group (appendix p 18). 21 (6%) of 374 patients in the regorafenib group had grade 3 or higher treatment-emergent bleeding events versus 15 (8%) of 193 patients in the placebo group (appendix p 18). 255 (68%) of 374 patients in the regorafenib group had interruptions or dose reductions due to adverse events versus 60 (31%) of 193 patients in the placebo group. Similarly, 93 (25%) of 374 patients in the regorafenib group discontinued due to adverse events versus 37 (19%) of 193 patients in the placebo group. Drug-related adverse events led to interruptions or dose reductions in 202 (54%) patients in the regorafenib group and 20 (10%) patients in the placebo group, and to discontinuations in 39 (10%) patients in the regorafenib group and seven (4%) patients in the placebo group. The most common adverse events leading to discontinuation more frequently with regorafenib were increase in AST concentration (eight [2%] of 374 patients in the regorafenib group vs three [2%] of 193 patients in the placebo group), hand-foot skin reaction (seven [2%] vs none), and ALT increase (four [1%] vs none).
No clinically meaningful diff erences were noted between the regorafenib and placebo groups in HRQoL. Overall changes from baseline in EQ-5D and FACT-Hep were similar in the two groups. In the LSM time-adjusted AUC analysis of the EQ-5D and FACT-Hep, the scores were lower in the regorafenib group than in the placebo group, and specifi cally the scores of the FACT-Hep Total and Trial Outcome Index (a subscale of the FACT-Hep) were statistically lower in the regorafenib group than in the placebo group (p=0·0006 and p<0·0001, respectively); however, minimally important thresholds for the diff erences as established in the literature were not met (appendix p 19). 24, 25 
Discussion
Our study shows that regorafenib provides a signifi cant and clinically meaningful improvement in overall survival in patients with HCC progressing during sorafenib treatment. This fi nding was associated with an increase in median survival from 7·8 months to 10·6 months. This survival benefi t was maintained in the prespecifi ed subgroup analyses, including geographical region and aetiology, and was accompanied by signifi cant improvements in progression-free survival, time to progression, and objective response, and disease control rate. Two patients treated with regorafenib had a complete tumour response by mRECIST, which excludes necrosis of the target lesion from the tumour measurement. These responses would also have been classifi ed as complete using conventional European Association for the Study of the Liver criteria. 27 Interestingly, we noted similar outcomes using mRECIST and RECIST 1.1 for progression-free survival and time to progression.
The survival of the placebo group in our study is consistent with previous second-line studies in HCC at about 8 months. [11] [12] [13] [14] Use of fi ve stratifi cation factors ensured that the trial groups were fully balanced for commonly assessed patient and disease characteristics; however, we also analysed the distribution of patients across treatment groups according to the pattern of progression under sorafenib. Pattern of progression has recently been found to be a major factor aff ecting outcome and potentially confounding study results if not balanced across study groups. 26 Although new intrahepatic sites or growth of known tumour lesions have been shown to have a moderate eff ect on postprogression survival, the development of new vascular invasion or extrahepatic spread is a signifi cant predictor of a worse survival. 26 Pattern of progression under previous sorafenib was balanced in this study.
All primary and secondary effi cacy outcomes in this sorafenib pretreated population seem numerically better than those with sorafenib in the fi rst-line setting. 4 active than is sorafenib, 15 and could also be because tolerability to regorafenib was improved for patients tolerant to sorafenib due to the somewhat overlapping adverse-event profi les of the two drugs. As multikinase inhibitors, the antitumour activity of regorafenib and sorafenib could extend beyond their antiangiogenic properties to a direct eff ect on tumour and stromal cells that modulate infl ammatory and immune processes. 28 Recent phase 3 trials in HCC assessing multikinase inhibitors having profi les that partly overlap with regorafenib have failed to improve outcomes over sorafenib or versus placebo after sorafenib. [6] [7] [8] 11 The results of this study suggest that the sequential use of two multikinase inhibitors with partly overlapping target profi les provides a survival benefi t in HCC. Regorafenib has been shown to improve survival in patients with gastrointestinal stromal tumours after failure of two multikinase inhibitors (imatinib and sunitinib). 19 This study was designed to assess a new systemic treatment for patients with HCC progressing on fi rstline therapy and incorporated lessons from previous phase 3 trials that failed to meet their primary endpoint. [6] [7] [8] [9] [10] [11] [12] [13] [14] Only patients with Child-Pugh A liver function were included to avoid the potential confounding eff ect of impaired liver function on survival. To ensure that treatment groups were balanced with respect to relevant prognostic factors, randomisation was stratifi ed by α-fetoprotein concentrations and ECOG performance status. However, unlike in previous studies, 4, 11 macrovascular invasion and extrahepatic disease were separate stratifi cation factors. We also stratifi ed for geographical region because of diff erences in access to cancer care and the use of locoregional therapies. Although the trial was not stratifi ed for aetiology, geographical region accounts partly for the aetiology of HCC because hepatitis B virus infection is the predominant underlying cause of HCC in most Asian countries.
The safety of regorafenib in HCC in this study is consistent with the safety profi le of regorafenib in other gastrointestinal malignancies, and with no new safety concerns. 18, 19 The most common grade 3 or 4 adverse events included hypertension, hand-foot skin reaction, fatigue, and diarrhoea. Exclusion of patients who were unable to tolerate sorafenib could have reduced the occurrence of severe adverse events; 10% of patients discontinued treatment due to a regorafenib-related adverse event. Although underlying liver dysfunction is expected to be more common in patients with HCC, the rates of liver-related adverse events and liver failure in the regorafenib group were not higher in this study compared with in other regorafenib trials. 18, 19 In this study, the only two cases of drug-related death due to liver failure occurred in the placebo group. Although adverse events in the regorafenib group led to higher rates of treatment interruptions and dose reductions than did those in the placebo group, the median treatment duration was longer with regorafenib than with placebo. Assessments using standard, validated measures of quality of life in patients with hepatobiliary cancer showed no clinically meaningful diff erences between the groups.
Although biomarker-based treatment decisions have become standard of care in certain tumour types, no baseline markers predictive of treatment benefi t have been identifi ed for patients with HCC. 29, 30 Exploratory studies have suggested that there is an association between certain adverse events, most notably hand-foot skin reaction, and overall survival and time to progression. 31 However, because this approach is based on post-randomisation events, it does not inform the selection of patients who could derive a greater treatment benefi t.
A potential limitation of the study is that it was undertaken in patients who progressed during previous sorafenib treatment, and therefore fi rm conclusions about the effi cacy of regorafenib in patients who do not tolerate sorafenib cannot be drawn. In addition, special populations, such as patients co-infected with HIV, are not included here.
The results of this study represent a signifi cant advance in addressing an unmet need in the treatment of HCC. All previous second-line trials of novel agents have failed; [11] [12] [13] [14] thus no eff ective systemic therapies after progression on sorafenib are currently available. These data underscore that prolonging exposure to multikinase inhibitors such as the sequence of sorafenib and regorafenib in conjunction with proper management of adverse events can lead to an extension in survival. In conclusion, this study met its primary endpoint showing that regorafenib improves overall survival in patients with HCC who had disease progression during fi rst-line treatment with sorafenib.
